2.6 KiB
ADR-0118: Funded cellular mutation transitions
Status
Accepted for the first M11 mutation implementation (2026-10-11). This is a versioned trial contract, not a balance sign-off. Mutation eligibility, offer timing and any tunable thresholds remain open for the 11.3 probe and 11.9 repeated-life review.
Context
ADR-0098 selects in-life mutation from seeded M3.4 offers and requires each
selection to be funded through development. select_mutation already returns an
immutable successor, while metabolic_budget derives the exact body inventory
from a genome and growth state. The missing pure step is the atomic inventory
proposal that joins them. A total-mass comparison is insufficient because one
channel cannot pay for another.
Decision
For a selected candidate, keep the organism's current growth state and derive both the current and successor body inventories under the same recorded environment. For each matter channel independently:
- A larger successor compartment is intake from the organism's reserve.
- A smaller successor compartment is released back to that reserve.
- A release in one channel cannot fund an intake in another channel.
Construction energy is the current development version's construction rate applied to the sum of the matter-channel intakes. It is charged from retained reserve. The transition is refused unless every matter channel and energy can be funded. No partial debit, growth change, or genome change is returned on refusal. On success, the caller receives a detached successor genome, exact successor body, exact new reserve, and the intake/release audit inventories. Only the authoritative owner may commit it.
This computes a trial cost from existing development and composition rules; it does not add a mutation-specific price or multiplier. The existing M3 catalog, seed, stream and event-index rules continue to determine the offer. Eligibility and event cadence are separate contracts and are not inferred from this cost proposal.
Consequences
Candidate generation and selection remain pure. The funder can be tested for channel conservation and refusal atomicity before session or persistence code is involved. A successor that costs more than its current reserve cannot be chosen until the organism has retained enough of every required resource. A future balance change requires a versioned development-rule review; no old genome is silently reinterpreted.
The transition does not yet create or persist player-facing offers, award eligibility, publish a genome revision, or define candidate UI. Those belong to later M11.4 segments.